UPS to invest $48 million in cold-chain logistics, adding 27 temperature-controlled facilities

UPS is committing about $48 million to build a new cold-chain logistics network aimed at healthcare shipments, including biological drugs and complex therapies that need temperature control. The plan centers on 27 temperature-controlled facilities, according to a report published by Yahoo Finance on June 24, 2026.

Cold-chain logistics refers to the packaging and transportation systems used to keep temperature-sensitive products within a required range from origin to destination. For healthcare customers, that typically includes pharmaceuticals and treatments whose effectiveness can be affected by heat, freezing, or time outside controlled conditions.

The investment is positioned as part of a broader operational push that includes “remaking” UPS deliveries in the United Kingdom. The Yahoo Finance piece links the cold-chain buildout to an overall modernization of delivery processes, while framing the healthcare infrastructure as a dedicated response to growing demand for temperature-controlled transportation.

The company’s stated target is healthcare transport, specifically shipments tied to biological drugs and other complex therapies. Biological products often have tighter requirements than traditional small-molecule pharmaceuticals, and they can require specialized packaging and monitoring throughout transit.

UPS did not, in the report, spell out the specific locations of the 27 facilities, their timelines, or the exact temperature ranges the infrastructure is designed to support. The piece also does not quantify expected revenue contribution, how much capacity the facilities add, or whether the network will serve only UPS-operated transportation or also third-party logistics flows.

For UPS, healthcare logistics is a strategically relevant niche within broader package delivery and supply-chain services. Temperature-controlled transportation adds operational complexity, including handling procedures, equipment reliability, and cold-chain monitoring, which can raise the cost to serve but can also create differentiation versus standard parcel networks.

The report’s framing suggests UPS is responding to customer and regulatory expectations around maintaining product integrity during shipping. Still, details on how the facilities will be integrated into UPS’s existing sorting, linehaul, and last-mile operations were not included in the published summary.

What to watch next is whether UPS provides additional specifics, such as facility locations, commissioning dates, technology standards for monitoring and compliance, and any new healthcare logistics service commitments it ties to the investment. Investors and customers will likely look for clearer guidance on expected scaling and performance metrics as the cold-chain buildout progresses.